Tech Transfer eNews Blog

Revive Therapeutics licenses cannabinoid-based treatment for liver disease from South Carolina Research Foundation

By Jesse Schwartz
Published: September 27th, 2017

Drug developer Revive Therapeutics has licensed a portfolio of patents from the South Carolina Research Foundation (SCRF) that cover cannabinoid-based therapeutics to treat liver disease.

Under the terms of the licensing deal, Revive will pay SCRF an upfront one-time fee, and all other payments will be based on clinical trial and revenue milestones the company reaches.

 “The licensing of this patent portfolio of cannabinoids in the treatment of liver diseases is an important milestone for Revive, as we continue to realize our objective of commercializing treatments to address unmet medical needs in liver diseases,” says Craig Leon, CEO of Revive.

 “We will continue focusing on commercializing our candidates of cannabinoid-based therapies and on expanding our product pipeline in the field of liver disease such as autoimmune hepatits, liver cirrhosis, non-alcoholic steatohepatitis and non-alcoholic fatty liver disease,” adds Leon.

Source: Marketwired

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment